XML 96 R82.htm IDEA: XBRL DOCUMENT
v3.26.1

COMMITMENTS AND CONTINGENCIES (Details) $ in Thousands | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Oct. 31, 2025 manufacturer certificate | Jul. 31, 2025 | Jun. 30, 2025 USD ($) | Mar. 31, 2025 USD ($) | Jun. 30, 2026 USD ($) | Sep. 30, 2025 USD ($) notice | Jun. 30, 2025 USD ($) | Jun. 30, 2026 USD ($) | Jun. 30, 2025 USD ($) | Dec. 31, 2017 USD ($) | Jan. 31, 2026 USD ($) | Apr. 07, 2025 period | Feb. 28, 2025 | Aug. 31, 2023 USD ($)
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Volumes distributed in US market in duration period |  |  |  |  |  |  |  |  |  |  |  | 12 months |  |
Increasing modestly period | period |  |  |  |  |  |  |  |  |  |  |  | 2 |  |
Agreement period of volumes distributed in market |  |  |  |  |  |  |  |  |  |  |  | 3 years |  |
Legal settlement |  |  |  |  | $ 0 |  | $ 0 | $ 0 | $ 7,000 |  |  |  |  |
Number of paragraph certification | certificate | 2 |  |  |  |  |  |  |  |  |  |  |  |  |
Number of generic drug manufacturers | manufacturer | 2 |  |  |  |  |  |  |  |  |  |  |  |  |
GQ Bio Therapeutics GmbH |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of voting interests acquired |  |  |  |  |  |  |  |  |  |  |  |  | 81.00% |
GQ Bio Therapeutics GmbH | GQ Bio Therapeutics GmbH |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of voting interests acquired |  |  |  |  |  |  |  |  |  |  |  |  | 81.00% |
Johnson & Johnson MedTech |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Mutual termination rights term |  | 1 year |  |  |  |  |  |  |  |  |  |  |  |
Johnson & Johnson MedTech | ZILRETTA |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Option extended term |  | 12 months |  |  |  |  |  |  |  |  |  |  |  |
GeneQuine | Achievement of Development and Regulatory Milestones | Flexion |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Achievement of commercial milestones (up to) |  |  |  |  |  |  |  |  |  | $ 56,000 |  |  |  |
GeneQuine | Initiation of a Phase 2 Clinical Trial | Flexion |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Achievement of commercial milestones (up to) |  |  |  |  |  |  |  |  |  | 4,500 |  |  |  |
GeneQuine | Development and Global Regulatory Approval Milestone Payments | Flexion |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Achievement of commercial milestones (up to) |  |  |  |  |  |  |  |  |  | 51,500 |  |  |  |
Baylor College of Medicine (Baylor) | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Range of milestone payment |  |  |  |  |  |  |  |  |  | 100 |  |  |  |
Baylor College of Medicine (Baylor) | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Range of milestone payment |  |  |  |  |  |  |  |  |  | $ 600 |  |  |  |
LG Chem, Partnership Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  |  |  |  |  |  |  | $ 2,000 |  |  |
MyoScience Milestone Litigation |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Repayments for royalties |  |  |  | $ 5,200 |  |  |  |  | $ 5,200 |  |  |  |  |
Research Development Foundation |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Repayments for royalties |  |  | $ 23,100 |  |  | $ 23,100 |  |  |  |  |  |  |  |
Expect to receive partial summary judgment |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 23,100
Additional interest payment |  |  | $ 5,200 |  |  | 5,200 |  |  |  |  |  |  |  |
Payment received |  |  |  |  |  | $ 28,300 |  |  |  |  |  |  |  |
Number of notices are filed | notice |  |  |  |  |  | 2 |  |  |  |  |  |  |  |

X
- Definition Represents the amount of milestone payments the Company is entitled to receive based on the terms of the agreement. + References No definition available. + Details
Name: | pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum
Namespace Prefix: | pcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Contractual Obligation, Minimum Monthly Commission, Duration + References No definition available. + Details
Name: | pcrx_ContractualObligationMinimumMonthlyCommissionDuration
Namespace Prefix: | pcrx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contractual Obligation, Mutual Termination Rights Term + References No definition available. + Details
Name: | pcrx_ContractualObligationMutualTerminationRightsTerm
Namespace Prefix: | pcrx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Litigation Settlement, Amount Expected To Be Awarded from Other Party + References No definition available. + Details
Name: | pcrx_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty
Namespace Prefix: | pcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Litigation Settlement, Volume-Limited, Increase Period + References No definition available. + Details
Name: | pcrx_LitigationSettlementVolumeLimitedIncreasePeriod
Namespace Prefix: | pcrx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition Litigation Settlement, Volume-Limited, Maximum Percentage, Period + References No definition available. + Details
Name: | pcrx_LitigationSettlementVolumeLimitedMaximumPercentagePeriod
Namespace Prefix: | pcrx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition Litigation Settlement, Volume-Limited, Number Of Moderate Increase Periods + References No definition available. + Details
Name: | pcrx_LitigationSettlementVolumeLimitedNumberOfModerateIncreasePeriods
Namespace Prefix: | pcrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Generic Drug Manufacturers + References No definition available. + Details
Name: | pcrx_NumberOfGenericDrugManufacturers
Namespace Prefix: | pcrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Paragraph IV Certifications + References No definition available. + Details
Name: | pcrx_NumberOfParagraphIVCertifications
Namespace Prefix: | pcrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue from Contract with Customer, Milestone Payments, Maximum + References No definition available. + Details
Name: | pcrx_RevenueFromContractWithCustomerMilestonePaymentsMaximum
Namespace Prefix: | pcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of voting equity interest acquired in business combination. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 38 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-38 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details
Name: | us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount awarded from other party in judgment or settlement of litigation. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementAmountAwardedFromOtherParty
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Interest expense (income) directly attributable to an award in settlement of litigation. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(6)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_LitigationSettlementInterest
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of loss from litigation settlement for amount awarded to other party. Excludes claims within an insurance entity's normal claims settlement process. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details
Name: | us-gaap_LitigationSettlementLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482645/405-30-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.W.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479583/944-40-S99-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 275 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of pending claims pertaining to a loss contingency. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 + Details
Name: | us-gaap_LossContingencyPendingClaimsNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Cash received for the settlement of litigation during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_ProceedsFromLegalSettlements
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=pcrx_GQBioTherapeuticsGmbHMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=pcrx_GQBioTherapeuticsGmbHMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=pcrx_JohnsonJohnsonMedTechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pcrx_ZILRETTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=pcrx_GeneQuineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=pcrx_FlexionTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pcrx_AchievementOfMilestoneAxis=pcrx_InitiationOfAPhase2ClinicalTrialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pcrx_AchievementOfMilestoneAxis=pcrx_DevelopmentAndGlobalRegulatoryApprovalMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=pcrx_BaylorCollegeOfMedicineBaylorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=pcrx_LGChemPartnershipAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=pcrx_MyoScienceMilestoneLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=pcrx_ResearchDevelopmentFoundationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |